The Global Multiple Sclerosis (MS) Treatment Market is undergoing a profound clinical shift as therapeutic goals move beyond mere relapse reduction toward achieving "No Evidence of Disease Activity" (NEDA). By 2026, the market is defined by the dominance of high-efficacy Disease-Modifying Therapies (DMTs) and a significant pivot toward oral and B-cell-targeting infusion treatments. https://www.databridgemarketresearch.com/